Hologic downgraded to Hold from Buy at Needham

Needham downgraded Hologic (HOLX) to Hold from Buy and removed the firm’s prior $90 price target The firm believes that Hologic is facing several headwinds that it believes will result in slower top and bottom line growth in calendar 2025, says the analyst. These include slower mammography gantry placements, slower cytology growth due to the proposed USPSTF recommendation changes, and slower operating margin improvement. Management effectively lowered its long-term revenue growth target from 5%-7% to mid-single digit growth, which the firm interprets as 4%-6%, and the firm expects growth to be below this range during 2025, the analyst added.